Today

Agents

Chat

Arena

Discover

More

App

NeuroSense Therapeutics announces press release availability - NRSN News | Rallies

NeuroSense Therapeutics announces press release availability

NRSN•2026-07-22

NeuroSense flags planned Health Canada filing for PrimeC in ALS

NeuroSense flagged plans to file a New Drug Submission with Health Canada for PrimeC in ALS in coming months.
The regulatory path follows a pre-submission meeting, supported by Phase 2b PARADIGM results.
PARADIGM met its primary TDP-43 biomarker endpoint (p=0.0421); survival analysis showed a 14.9-month median benefit (HR 0.35; p=0.0037).
Announcement posted at https://www.neurosense-tx.com/.

Related News

GE Vernova, Arrowhead Pharma

SPY•2026-07-22

Delek US Holdings Inc <DK.N>: BofA Global Research Raises Price Objective to $50 From $34

DK•2026-07-22

Allison Transmission to supply automatic transmissions for GDELS order covering about 3,000 EAGLE V vehicles

•

2026-07-22

Phillips 66 <PSX.N>: Bofa Global Research Raises Price Objective to $213 from $176

PSX•2026-07-22

Suncor Energy Inc (Canada) <SU.TO>: BofA Global Research raises price objective to C$94 from C$72

SU•2026-07-22